

## REMARKS

In filing this RCE Applicants respectfully request entry of the October 3, 2006 Amendment. Reconsideration and withdrawal of all pending rejections are respectfully requested.

By the October 3, 2006 amendment claims 1, 3 and 4 were amended; at this time claims 1-8 are pending.

### Response to Advisory Action

The Advisory Action on the Continuation Sheet (PTO-303) asserted:

Continuation of 3. NOTE: Claim 4 is drawn to a transgenic non-human mammal comprising at least 3 mutations in PS1. However, in looking at the specification, nothing contemplates transgenic non-human mammals with any 3 mutations in PS1. Also, the new limitation of "at least three mutations" in claim 4 require (sic) a new search and consideration.

In Applicants October 3, 2006 Reply, direction to find support for the claim amendments was given as, "for example, in the original claims and at page 4, lines 4 and 5, and the last full sentence." Applicants respectfully assert that the specification at page 4, last full sentence clearly contemplates PS1 protein comprising at least three mutations.

Notably, page 4, last full sentence (a sentence specifically noted in the October 3, 2006 Amendment), states: "Multimutated protein is understood to mean the **PS1 protein comprising at least three mutations** which are combined or associated with each other, that is to say which are present at the same time in said protein." [Bolding added.] Accordingly, Applicants respectfully request reconsideration and withdrawal of the "Continuation of 3. NOTE".

### Conclusion

In view of the above amendments and remarks, Applicants respectfully submit that the application is now in condition for allowance and request prompt issuance of a Notice of Allowance. Should the Examiner wish to suggest additional changes that might put the application in even better condition for allowance, the Examiner is requested to contact the undersigned at the telephone number listed below.

The Commissioner is hereby authorized to charge the fee required and any additional fees that may be needed to Deposit Account No. 18-1982.

Respectfully submitted,

Dated: February 21, 2007

  
George S. Jones, Reg. No. 38,508  
Attorney for Applicants

sanofi aventisU.S. LLC  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone: 908-231-3776  
Telefax: 908-231-2626  
sanofi-aventis Docket No. **ST99042 US PCT**